The Oncosearch | Oncotarget

Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights into RTK dependent and independent mechanisms Review

Shreya Shyamsunder, Zhixin Lu, Vinita Takiar, Susan E. Waltz

Published Jun 16, 2025 · Vol. 16, No. 1 · pp. 508-530

Keywords: EGFR, RTKs, breast cancer, head and neck cancer, resistance mechanisms

Correction: Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b Correction

Elisabetta Vergani, Lorenza Di Guardo, Matteo Dugo, Sara Rigoletto, Gabrina Tragni, Roberta Ruggeri, Federica Perrone, Elena Tamborini, Annunziata Gloghini, Flavio Arienti, Barbara Vergani, Paola Deho, Loris De Cecco, Viviana Vallacchi, Paola Frati, Eriomina Shahaj, Antonello Villa, Mario Santinami, Filippo De Braud, Licia Rivoltini, Monica Rodolfo

Published Jun 10, 2025 · Vol. 16, No. 1 · pp. 443-444

Correction: Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2 Correction

Yan Luo, Lei Liu, Yang Wu, Karnika Singh, Bing Su, Nan Zhang, Xiaowei Liu, Yangmei Shen, Shile Huang

Published Jun 10, 2025 · Vol. 16, No. 1 · pp. 425-426

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment Precision Oncology

Alberto Hernando-Calvo, Razelle Kurzrock, Nadia Saoudi Gonzalez, Shai Magidi, Catherine Bresson, Fanny Wunder, Giulia Pretelli, Agatha Martin Casado, Wafik S. El-Deiry

Published Jun 9, 2025 · Vol. 16, No. 1 · pp. 456-466

Keywords: cancer, precision oncology, molecular tumor board, colorectal carcinoma, cancer management

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment Case Report

Alberto Hernando-Calvo, Razelle Kurzrock, Nadia Saoudi Gonzalez, Shai Magidi, Catherine Bresson, Fanny Wunder, Giulia Pretelli, Agatha Martin Casado, Wafik S. El-Deiry

Published Jun 9, 2025

Keywords: cancer, precision oncology, molecular tumor board, colorectal carcinoma, cancer management

Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience Research Paper

Fei Fei, Milhan Telatar, Vanina Tomasian, Lisa Chang, Olga Danilova, Javier Arias-Stella, Raju Pillai, Lorinda Soma, Parastou Tizro, Pamela S. Becker, Anthony S. Stein, Guido Marcucci, Michelle Afkhami

Published Jun 7, 2025 · Vol. 16, No. 1 · pp. 495-507

Keywords: Blastic plasmacytoid dendritic cell neoplasm (BPDCN), Next-generation sequencing (NGS), CCDC50

Optimizing enfortumab vedotin plus pembrolizumab therapy Review

Elias Antoine Karam, Yaghi César Céline, Gilles Prince, Fouad Attieh, Hampig Raphael Kourie, Joseph Kattan, Elie Nemer

Published Jun 5, 2025 · Vol. 16, No. 1 · pp. 481-494

Keywords: advanced urothelial carcinoma (aUC), enfortumab vedotin, pembrolizumab, treatment strategies

Beyond DNA damage response: Immunomodulatory attributes of CHEK2 in solid tumors Review

Helen Qian, Heba Ali, Vivekanudeep Karri, Justin T. Low, David M. Ashley, Amy B. Heimberger, Lucy A. Godley, Adam M. Sonabend, Crismita Dmello

Published Jun 5, 2025 · Vol. 16, No. 1 · pp. 445-453

Keywords: CHEK2, immune checkpoint inhibitors, immunomodulation

Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence Research Paper

Kavin Sugumar, Andrew Alabd, Andre Alabd, Jonathan J. Hue, Josh Lyons, Sherri Fields, Zev Wainberg, Lei Zheng, Brianna Coogle, Anup Kasi, Nicholas Grewal, Hedy L. Kindler, Jason Starr, Ashwin R. Sama, Jordan M. Winter

Published Jun 3, 2025 · Vol. 16, No. 1 · pp. 427-442

Keywords: pancreatic adenocarcinoma, immunotherapy, exceptional responders, microsatellite instability, survival

Applying the unattainable triangle in cardio-oncology care: Balancing cost, quality, and time Review

John Hoverson, Chirag Buch, Juan Ulloa-Rodriguez, Samuel Governor, Stella Pak, Prince Otchere

Published Jun 2, 2025 · Vol. 16, No. 1 · pp. 419-424

Keywords: cardio-oncology, quality improvement, cardiology, oncology

Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights Research Paper

Cleto Dantas Nogueira, Samuel Frota, Huylmer Lucena Chaves, Juliana Cordeiro de Sousa, Guilherme de Sousa Veloso, Francisco Jonathan dos Santos Araujo, Gabriel Barbosa Silva, Samuel Silva Ferreira, Marclesson Santos Alves, Fabio Nasser, Ezequiel Rangel, Francisco Martins Neto, Iusta Caminha, Ellen Nascimento, Fabio Tavora

Published May 31, 2025 · Vol. 16, No. 1 · pp. 467-479

Keywords: HER2 mutation, NSCLC, lung cancer, targeted therapy, genomic profiling

Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib Research Paper

Jinah Kim, Liam Il-Young Chung, Horyun Choi, Yoonhee Choi, Maria Jose Aguilera Chuchuca, Youjin Oh, Young Kwang Chae

Published May 21, 2025 · Vol. 16, No. 1 · pp. 411-418

Keywords: amivantamab, monotherapy, rare EGFR mutation, NSCLC, leptomeningeal disease

Correction: Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression Correction

María Laura Polo, Marina Riggio, María May, María Jimena Rodríguez, María Cecilia Perrone, Melody Stallings-Mann, Diego Kaen, Marlene Frost, Matthew Goetz, Judy Boughey, Claudia Lanari, Derek Radisky, Virginia Novaro

Published May 20, 2025 · Vol. 16, No. 1 · pp. 379-381

Retraction: RAB22A overexpression promotes the tumor growth of melanoma Retraction

Feng Su, Yifei Chen, Shilin Zhu, Fangfang Li, Shuang Zhao, Lisa Wu, Xiang Chen, Juan Su

Published May 17, 2025 · Vol. 16, No. 1 · pp. 347-347

Cigarette smoke and decreased DNA repair by Xeroderma Pigmentosum Group C use a double hit mechanism for epithelial cell lung carcinogenesis Research Paper

Nawar Al Nasrallah, Bowa Lee, Benjamin M. Wiese, Marie N. Karam, Elizabeth A. Mickler, Huaxin Zhou, Nicki Paolelli, Robert S. Stearman, Mark W. Geraci, Catherine R. Sears

Published May 9, 2025 · Vol. 16, No. 1 · pp. 396-409

Keywords: DNA repair, DNA damage, lung adenocarcinoma, squamous cell carcinoma, Xeroderma Pigmentosum Group C (XPC)

Advancements in bladder cancer treatment: The synergy of radiation and immunotherapy Review

Nazmul Hasan, Daniel Yang, Spencer Gibson, Barbod Khaleghi, Rozhan Ziari, Arash Rezazadeh Kalebasty

Published May 8, 2025 · Vol. 16, No. 1 · pp. 337-346

Keywords: bladder cancer, immunotherapy, radiation, microenvironment, abscopal

Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration resistant prostate cancer cells Research Paper

Shan Lu, Zhongyun Dong

Published May 8, 2025 · Vol. 16, No. 1 · pp. 383-395

Keywords: PCNA, androgen receptor, PCNA inhibitors, AR splicing variants, CRPC

Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma Research Paper

Leonardo Gomes da Fonseca, Federico Piñero, Margarita Anders, Carla Bermudez, Ezequiel Demirdjian, Adriana Varón, Daniela Perez, Jorge Rodriguez, Oscar Beltrán, Ezequiel Ridruejo, Pablo Caballini, Alexandre Araujo, Juan Diego Torres Florez, Juan Ignacio Marín, Marina Villa, Federico Orozco, Jaime Poniachik, Sebastián Marciano, Fernando Bessone, Manuel Mendizabal

Published May 8, 2025 · Vol. 16, No. 1 · pp. 348-360

Keywords: liver cancer, immunotherapy, adverse events, immunology, real-world

PRDX1 protects ATM from arsenite-induced proteotoxicity and maintains its stability during DNA damage signaling Research Paper

Reem Ali, Mashael Algethami, Amera Sheha, Shatha Alqahtani, Ahmad Altayyar, Ayat Lashen, Emad Rakha, Abdallah Alhaj Sulaiman, Srinivasan Madhusudan, Dindial Ramotar

Published May 3, 2025 · Vol. 16, No. 1 · pp. 362-378

Keywords: redox signaling, homologous recombination, protein interaction, cell cycle, protein modification

Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies Research Paper

Nina Klimova, Sandra Close, David M. Kurtz, Richard D. Hockett, Laura Hyland

Published May 2, 2025 · Vol. 16, No. 1 · pp. 329-336

Keywords: MRD, ctDNA, PhasED-Seq, CLARITY, residual disease

Publication Alerts

European Cancer and Oncology Congress

Post-Publication Promotion

Search Oncotarget

Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights into RTK dependent and independent mechanisms Review

Correction: Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b Correction

Correction: Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2 Correction

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment Precision Oncology

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment Case Report

Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience Research Paper

Optimizing enfortumab vedotin plus pembrolizumab therapy Review

Beyond DNA damage response: Immunomodulatory attributes of CHEK2 in solid tumors Review

Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence Research Paper

Applying the unattainable triangle in cardio-oncology care: Balancing cost, quality, and time Review

Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights Research Paper

Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib Research Paper

Correction: Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression Correction

Retraction: RAB22A overexpression promotes the tumor growth of melanoma Retraction

Cigarette smoke and decreased DNA repair by Xeroderma Pigmentosum Group C use a double hit mechanism for epithelial cell lung carcinogenesis Research Paper

Advancements in bladder cancer treatment: The synergy of radiation and immunotherapy Review

Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration resistant prostate cancer cells Research Paper

Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma Research Paper

PRDX1 protects ATM from arsenite-induced proteotoxicity and maintains its stability during DNA damage signaling Research Paper

Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies Research Paper

Publication Alerts

European Cancer and Oncology Congress

Oncoscience

Post-Publication Promotion

Search Oncotarget

Challenges and resistance mechanisms to EGFR targeted therapies in head and neck cancers and breast cancer: Insights into RTK dependent and independent mechanisms Review

Correction: Overcoming melanoma resistance to vemurafenib by targeting CCL2-induced miR-34a, miR-100 and miR-125b Correction

Correction: Rapamycin inhibits mSin1 phosphorylation independently of mTORC1 and mTORC2 Correction

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment Precision Oncology

Case Report WIN-MTB-2023001 WIN International Molecular Tumor Board A 62-year-old male with metastatic colorectal cancer with 5 prior lines of treatment Case Report

Genetic characteristics of blastic plasmacytoid dendritic cell neoplasm: A single institution experience Research Paper

Optimizing enfortumab vedotin plus pembrolizumab therapy Review

Beyond DNA damage response: Immunomodulatory attributes of CHEK2 in solid tumors Review

Exceptional responders to immunotherapy in pancreatic cancer: A multi-institutional case series of a rare occurrence Research Paper

Applying the unattainable triangle in cardio-oncology care: Balancing cost, quality, and time Review

Molecular landscape of HER2-mutated non-small cell lung cancer in Northeastern Brazil: Clinical, histopathological, and genomic insights Research Paper

Durable complete response in leptomeningeal disease of EGFR mutated non-small cell lung cancer to amivantamab, an EGFR-MET receptor bispecific antibody, after progressing on osimertinib Research Paper

Correction: Activation of PI3K/Akt/mTOR signaling in the tumor stroma drives endocrine therapy-dependent breast tumor regression Correction

Retraction: RAB22A overexpression promotes the tumor growth of melanoma Retraction

Cigarette smoke and decreased DNA repair by Xeroderma Pigmentosum Group C use a double hit mechanism for epithelial cell lung carcinogenesis Research Paper

Advancements in bladder cancer treatment: The synergy of radiation and immunotherapy Review

Targeting PCNA/AR interaction inhibits AR-mediated signaling in castration resistant prostate cancer cells Research Paper

Immune-mediated adverse events following atezolizumab and bevacizumab in a multinational Latin American cohort of unresectable hepatocellular carcinoma Research Paper

PRDX1 protects ATM from arsenite-induced proteotoxicity and maintains its stability during DNA damage signaling Research Paper

Analytical validation of a circulating tumor DNA assay using PhasED-Seq technology for detecting residual disease in B-cell malignancies Research Paper